Germany
· Delayed Price · Currency is EUR | Market Cap | 116.57B |
| Revenue (ttm) | 57.67B |
| Net Income (ttm) | 7.28B |
| Shares Out | n/a |
| EPS (ttm) | 1.28 |
| PE Ratio | 16.02 |
| Forward PE | 8.19 |
| Dividend | 1.57 (7.63%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 11,812 |
| Average Volume | 90,112 |
| Open | 20.27 |
| Previous Close | 20.27 |
| Day's Range | 20.23 - 20.66 |
| 52-Week Range | 18.57 - 29.50 |
| Beta | n/a |
| RSI | 49.26 |
| Earnings Date | Jul 29, 2025 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial numbers in USD Financial StatementsNews
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
Strong Cresemba (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea
Allschwil, Switzerland, June 05, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial an...
These Stocks Are The High-Yield Dividend Investor's Best Friend
High-yield stocks are often riddled with flaws. However, there are some high-yield stocks available today that check all of my boxes. I share some of my top high-yield picks of the moment.
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
PHILADELPHIA , June 3, 2025 /PRNewswire/ -- Berger Montague advises shareholders of Pfizer Inc. ("Pfizer" or the "Company") (NYSE: PFE) about an investigation into Pfizer's Board of Directors for pot...
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.
Pfizer: I Should Have Sold Earlier (Downgrade)
Pfizer's R&D Optimization Delivers Great Results & Secure Dividends
Takeda, Pfizer's Adcetrix wins EU approval for hodgkin lymphoma treatment
Buy, Sell, Or Hold PFE Stock At $23?
Pfizer (NYSE:PFE) stock is down around 25% from its 52-week high of over $31 to $23 now. Pipeline setbacks, including an experimental treatment for Duchenne muscular dystrophy (DMD) failing in a late-...
CERE Investors Have the Opportunity to Lead the Cerevel Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE), Bain Capital In...
June's Top 10 High-Yield Stocks: Build A Path To A 10%+ Yield By 2035
My top 10 high-yield picks for June 2025 balance attractive dividend yields, strong financials, and competitive advantages to reduce risk and enhance returns. I use a rigorous four-step selection proc...
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 46th Annual Globa...
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Gold...
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race
Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer’s deal announced two weeks earlier.
A ‘war on children’: as US changes Covid vaccine rules, parents of trial volunteers push back
Frustration and anger mount as Trump administration contemplates new trials and restrictions for Covid vaccines As the Trump administration contemplates new clinical trials for Covid boosters and move...
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Cerevel To Contact Him Directly To Discuss Their Options A class action w...
Terrible News for Pfizer Stock Investors
Pfizer/Arvinas to seek FDA nod for jointly developed cancer therapy in H2
Pfizer (PFE) CEO on Braftovi Reducing Colorectal Cancer Death Risk "in Half"
Dr. Albert Bourla, CEO of Pfizer (PFE), joins Nicole Petallides on Morning Trade Live to discuss the latest results of his company's Braftovi drug trials. According to Dr. Bourla, results showed it ca...
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression
An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to AstraZeneca's Faslodex in patients with a specific gene mutation, according t...
Carat Group's Fred Hassan dives into what pharma companies to watch at 2025 ASCO Annual Meeting
Fred Hassan, Carat Group chairman, joins 'Money Movers' to discuss pharma innovation in 2025 and what companies he's watching in the sector.
Pfizer meets main goals in colorectal cancer treatment
Pfizer's Oral Obesity Drug Flop - A Symptom Of A Deeper Pipeline Problem
Pfizer’s BRAFTOVI Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with cet...
Advanced colon cancer patients lived twice as long with a Pfizer combo therapy, trial finds
A combination drug treatment doubled survival time for patients with an aggressive form of colorectal cancer, according to late-stage trial data published Friday.